Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company

Legend Biotech No Longer Faces Delisting from Nasdaq

Fineline Cube Feb 22, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released a notice stating that it is no...

Company Drug

Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA

Fineline Cube Feb 22, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...

Company Medical Device

MicroPort CardioFlow’s TAVI Product Approved in Thailand

Fineline Cube Feb 22, 2023

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has...

Company Deals

TransThera Biosciences Completes Series D+ Financing Round

Fineline Cube Feb 22, 2023

China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...

Company Drug

Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance

Fineline Cube Feb 22, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...

Company Deals

Huahai Pharma Raises Funds for Digital Manufacturing and API Platform

Fineline Cube Feb 22, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...

Company Deals R&D

Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center

Fineline Cube Feb 22, 2023

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...

Company Drug

Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing

Fineline Cube Feb 22, 2023

February 23 will mark the oral hearing phase for the patent challenge case brought by...

Company Drug

Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment

Fineline Cube Feb 22, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...

Company Drug

Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt

Fineline Cube Feb 22, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced obtaining market approval from the Egyptian Drug...

Company Medical Device

Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval

Fineline Cube Feb 22, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Company Deals

Merck KGaA Partners with Beijing for Drug Imports via Beijing Ports

Fineline Cube Feb 22, 2023

Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the...

Company Drug

Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials

Fineline Cube Feb 22, 2023

China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...

Company Deals

Meihua International Partners with Hainan for Medical Tech Park and R&D Center

Fineline Cube Feb 22, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has...

Company Deals

Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership

Fineline Cube Feb 22, 2023

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...

Drug Policy / Regulatory

CDE Releases 67th Batch of Chemical Generic Reference Preparations

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the 67th batch of chemical generic reference...

Drug

CDE Releases Guidelines for Chemically Synthesized Peptide Research

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Pharmaceutical Research of...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study

Fineline Cube Feb 21, 2023

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...

Company Deals

Abbott Partners with Sinopharm for Expanded Medical Solutions in China

Fineline Cube Feb 21, 2023

US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...

Company Drug

Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment

Fineline Cube Feb 21, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...

Posts pagination

1 … 551 552 553 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.